Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs. This may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action.
These factors can be of different types:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2 | Experimental | T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2 |
|
| Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1 | Experimental | T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2 |
|
| Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2 | Experimental | T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2 |
|
| Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2 | Experimental | T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Indapamide (T2) | Drug | 1.5 mg/day during 4 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure at the end of each 4 week treatment period | Change from baseline and after each 4 week treatment period | 16 weeks |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Francois GUEYFFIER, MD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Louis Pradel | Bron | 69677 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24739801 | Result | Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007190 | Indapamide |
| D020913 | Perindopril |
| C020845 | P-2 |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013450 | Sulfones |
| D013457 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Perindopril (T1) | Drug | 4 mg/day during 1 week then 8 mg/day during 3 weeks |
|
| Placebo of Perindopril (P1) | Drug | 1 pill/day during 1 week then 2 pills/day during 3 weeks |
|
| Placebo of Indapamide (P2) | Drug | 1 pill/day during 4 weeks |
|
| Sulfur Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |